{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T22:56:16Z","timestamp":1765666576351},"reference-count":26,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2002,1,4]],"date-time":"2002-01-04T00:00:00Z","timestamp":1010102400000},"content-version":"vor","delay-in-days":1130,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[1998,12]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>The most extensively studied<jats:italic>Helicobacter pylori<\/jats:italic>eradication regimen comprises omeprazole, clarithromycin and metronidazole. Macrolide antibiotics other than clarithromycin should achieve similar efficacy, but they have not yet been thoroughly tested.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>To determine the efficacy and safety of a triple therapy regimen using lansoprazole, roxithromycin, and metronidazole on the basis of multicentre out\u2010patient care in an open pilot study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>163 patients with duodenal ulcer and proven<jats:italic>H. pylori<\/jats:italic>infection received lansoprazole 30\u2003mg b.d., roxithromycin 300\u2003mg b.d. and metronidazole 500\u2003mg b.d. for 7\u2003days followed by another 7 days of lansoprazole 30\u2003mg once daily.<jats:italic>H. pylori<\/jats:italic>status was determined by urease quick test, histology, microbiology and<jats:sup>13<\/jats:sup>C\u2010urea breath test before starting and at least 4\u2003weeks after completing treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>150 patients were available for evaluation;<jats:italic>H. pylori<\/jats:italic>was successfully eradicated in 84.7% (127\/150) as determined by urease quick test, 78.0% (117\/150) by histology, 81.3% (109\/134) by<jats:sup>13<\/jats:sup>C\u2010urea breath test; and in 75.3% (113\/150), at least two tests were negative. Side\u2010effects were reported in 34 patients (most commonly diarrhoea and changes in liver function tests), in two cases the study medication was interrupted. Prior to treatment, 23% of the<jats:italic>H. pylori<\/jats:italic>isolates were resistant against metronidazole and 3.4% against roxithromycin. After unsuccessful treatment, 84% of the isolates were resistant against metronidazole and 21% against roxithromycin. Primary resistance to metronidazole increased the chance of treatment failure approximately sevenfold (7% vs. 53%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>For<jats:italic>H. pylori<\/jats:italic>eradication, the combination of lansoprazole, roxithromycin and metronidazole proved to be as safe as other current triple therapy regimens, while a comparison of efficacy rates yet remains to be assessed in prospective controlled trials. The metronidazole\u2010resistant<jats:italic>H. pylori<\/jats:italic>is not rare in Germany and, in the present study, has strongly influenced treatment success.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.1998.00433.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:36:06Z","timestamp":1047353766000},"page":"1273-1278","source":"Crossref","is-referenced-by-count":14,"title":["Eradication of<i>Helicobacter pylori<\/i>with lansoprazole, roxithromycin and metronidazole\u2014an open pilot study"],"prefix":"10.1111","volume":"12","author":[{"family":"Pohle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Stoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Heep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Lehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Bock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Domschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,1,4]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91111-8"},{"key":"e_1_2_6_3_2","first-page":"392","article-title":"Diagnostik und Therapie der Helicobacter\u2010pylori\u2010Infektion","volume":"34","author":"Caspary W","year":"1996","journal-title":"Z Gastroenterol"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199306000-00004"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199448020-00011"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02114894"},{"key":"e_1_2_6_7_2","first-page":"32","article-title":"Effect of lansoprazole on Helicobacter pylori","volume":"15","author":"Lamouilatte H.","year":"1993","journal-title":"Clin Ther"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1994.tb00293.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365529509093265"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199448030-00007"},{"key":"e_1_2_6_11_2","doi-asserted-by":"crossref","unstructured":"WarrenJR&MarshallB.Unidentified curved bacilli on gastric epithelium in active chronic gastritis.Lancet1983; ii: 1273\u20135.","DOI":"10.1016\/S0140-6736(83)92719-8"},{"key":"e_1_2_6_12_2","first-page":"79","volume":"47","author":"Hilker E","year":"1996","journal-title":"J Physiol Pharmacol"},{"key":"e_1_2_6_13_2","first-page":"1245","article-title":"Testing for Helicobacter pylori infection after antibiotic treatment","volume":"92","author":"Katelaries PH","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_6_14_2","first-page":"73","article-title":"Omeprazole modified antibiotic therapy of Helicobacter pylori infection: can clarithromycin be replaced by roxithromycin?","volume":"24","author":"Labenz J","year":"1994","journal-title":"Leber Magen Darm"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1995.tb00372.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","unstructured":"CaselliM TrevisaniL TursiA et al.Short\u2010term low\u2010dose triple therapy with azithromycin metronidazole and lansoprazole appears highly effective for the eradication ofHelicobacter pylori.Eur J Gastroenterol Hepatol1997; 9: 45\u20138.","DOI":"10.1097\/00042737-199701000-00012"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","unstructured":"YousfiMM El\u2010ZimaityHM Al\u2010AssiMT ColeRA GentaRM GrahamDY.Metronidazole omeprazole and clarithromycin: an effective combination therapy forHelicobacter pyloriinfection.Aliment Pharmacol Ther1995; 9: 209\u201312.","DOI":"10.1111\/j.1365-2036.1995.tb00374.x"},{"key":"e_1_2_6_18_2","unstructured":"TreiberG.The influence of drug dosage onHelicobacter pylorieradication: a cost\u2010effectiveness analysis.Am J Gastroenterol1996; 91: 246\u201357."},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","unstructured":"LabenzJ TillenburgB Weism\u00fcllerJ L\u00fctkeA StolteM.Efficacy and tolerability of a one\u2010week triple therapy consisting of pantoprazole clarithromycin and amoxycillin for cure ofHelicobacter pyloriinfection in patients with duodenal ulcer.Aliment Pharmacol Ther1997; 11: 95\u2013100.","DOI":"10.1046\/j.1365-2036.1997.130301000.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"crossref","unstructured":"WaltRP.Metronidazole\u2010resistantH.pylori\u2014of questionable clinical importance.Lancet1996; 348: 489\u201390.","DOI":"10.1016\/S0140-6736(05)64665-X"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199506001-00007"},{"key":"e_1_2_6_22_2","unstructured":"BuckleyMJM XiaHX HydeDM KeaneCT O\u2019MorainCA.Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance.Dig Dis Sci1997; 42: 2111\u201315."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.1.250"},{"key":"e_1_2_6_24_2","article-title":"The MACH 2 study. Helicobacter pylori resistance to antimicrobial agents and its influence on clinical outcome","volume":"112","author":"Megraud F","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_6_25_2","doi-asserted-by":"crossref","unstructured":"AdamekRJ SuerbaumS PfaffenbachB WegenerM OpferkuchW.Primary and acquiredH. pyloriresistance to clarithromycin metronidazole and amoxicillin\u2014influence on treatment outcome.Am J Gastroenterol1998; 93: 386\u20139.","DOI":"10.1016\/S0002-9270(97)00110-X"},{"key":"e_1_2_6_26_2","article-title":"Geographical distribution in the United States of primary resistance to clarithromycin and metronidazole in patients infected with Helicobacter pylori","volume":"112","author":"Weissfeld A","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_6_27_2","article-title":"Metronidazole and clarithromycin resistance among H. pylori isolates from a large hospital in the United States","volume":"112","author":"Osato MS","year":"1997","journal-title":"Gastroenterology"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1998.00433.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.1998.00433.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.1998.00433.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T20:41:32Z","timestamp":1704314492000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.1998.00433.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[1998,12]]}},"alternative-id":["10.1046\/j.1365-2036.1998.00433.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.1998.00433.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,12]]}}}